Laura M Raffield1, Gretchen A Brenes2, Amanda J Cox3, Barry I Freedman4, Christina E Hugenschmidt5, Fang-Chi Hsu6, Jianzhao Xu7, Benjamin C Wagner8, Jeff D Williamson5, Joseph A Maldjian8, Donald W Bowden9. 1. Molecular Genetics and Genomics Program, Wake Forest School of Medicine, Winston-Salem, NC, USA; Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. 2. Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. 3. Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. 4. Department of Internal Medicine - Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Department of Gerontology and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA. 6. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 7. Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. 8. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 9. Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: dbowden@wakehealth.edu.
Abstract
AIMS: Anxiety, depression, accelerated cognitive decline, and increased risk of dementia are observed in individuals with type 2 diabetes. Anxiety and depression may contribute to lower performance on cognitive tests and differences in neuroimaging observed in individuals with type 2 diabetes. METHODS: These relationships were assessed in 655 European Americans with type 2 diabetes from 504 Diabetes Heart Study families. Participants completed cognitive testing, brain magnetic resonance imaging, the Brief Symptom Inventory Anxiety subscale, and the Center for Epidemiologic Studies Depression-10. RESULTS: In analyses adjusted for age, sex, educational attainment, and use of psychotropic medications, individuals with comorbid anxiety and depression symptoms had lower performance on all cognitive testing measures assessed (p≤0.005). Those with both anxiety and depression also had increased white matter lesion volume (p=0.015), decreased gray matter cerebral blood flow (p=4.43×10(-6)), decreased gray matter volume (p=0.002), increased white and gray matter mean diffusivity (p≤0.001), and decreased white matter fractional anisotropy (p=7.79×10(-4)). These associations were somewhat attenuated upon further adjustment for health status related covariates. CONCLUSIONS: Comorbid anxiety and depression symptoms were associated with cognitive performance and brain structure in a European American cohort with type 2 diabetes.
AIMS: Anxiety, depression, accelerated cognitive decline, and increased risk of dementia are observed in individuals with type 2 diabetes. Anxiety and depression may contribute to lower performance on cognitive tests and differences in neuroimaging observed in individuals with type 2 diabetes. METHODS: These relationships were assessed in 655 European Americans with type 2 diabetes from 504 Diabetes Heart Study families. Participants completed cognitive testing, brain magnetic resonance imaging, the Brief Symptom Inventory Anxiety subscale, and the Center for Epidemiologic Studies Depression-10. RESULTS: In analyses adjusted for age, sex, educational attainment, and use of psychotropic medications, individuals with comorbid anxiety and depression symptoms had lower performance on all cognitive testing measures assessed (p≤0.005). Those with both anxiety and depression also had increased white matter lesion volume (p=0.015), decreased gray matter cerebral blood flow (p=4.43×10(-6)), decreased gray matter volume (p=0.002), increased white and gray matter mean diffusivity (p≤0.001), and decreased white matter fractional anisotropy (p=7.79×10(-4)). These associations were somewhat attenuated upon further adjustment for health status related covariates. CONCLUSIONS: Comorbid anxiety and depression symptoms were associated with cognitive performance and brain structure in a European American cohort with type 2 diabetes.
Authors: Joseph A Maldjian; Paul J Laurienti; Jonathan H Burdette; Robert A Kraft Journal: J Comput Assist Tomogr Date: 2008 May-Jun Impact factor: 1.826
Authors: Warren D Taylor; James R MacFall; Martha E Payne; Douglas R McQuoid; David C Steffens; James M Provenzale; Ranga Rama Krishnan Journal: Psychiatry Res Date: 2005-05-30 Impact factor: 3.222
Authors: Nina Buscemi; Ben Vandermeer; Carol Friesen; Liza Bialy; Michelle Tubman; Maria Ospina; Terry P Klassen; Manisha Witmans Journal: J Gen Intern Med Date: 2007-07-10 Impact factor: 5.128
Authors: Abdulmajeed Alotaibi; Christopher Tench; Rebecca Stevenson; Ghadah Felmban; Amjad Altokhis; Ali Aldhebaib; Rob A Dineen; Cris S Constantinescu Journal: Brain Sci Date: 2021-01-22